On July 17, 2025, the American Heart Association published a science advisory formally connecting the composition of gut bacteria to blood pressure regulation, a move that reframes how physicians and patients think about treating hypertension. The advisory draws on years of accumulated research, including a population study of 6,953 adults that tracked specific bacterial genera alongside blood pressure readings and sodium intake. For the roughly half of American adults living with high blood pressure, the question is no longer whether gut microbes play a role but how large that role is and what, if anything, people can do about it right now.
Why gut bacteria and blood pressure are linked in AHA guidance
The AHA advisory did not emerge from a single experiment. It reflects a body of evidence that has grown steadily over the past several years, connecting dietary salt, immune activation, and bacterial populations inside the intestine to measurable changes in blood pressure. A large cohort analysis of 6,953 individuals published in the Journal of the American Heart Association found that specific gut microbiota features, including the abundance of Lactobacillus at the genus and species level, tracked with blood pressure indices. That same study used 24-hour urinary sodium measurements in a subsample to account for salt intake, strengthening the case that the bacterial signal was not simply a proxy for diet.
Separately, experimental work in Nature showed that high-salt feeding depleted Lactobacillus populations in the gut while activating the Th17 immune axis, a pathway that promotes inflammation and vascular stiffness. That study included a small human salt-challenge component, giving the findings direct relevance beyond animal models. Together, these lines of evidence suggest a feedback loop: excess sodium reshapes the gut microbiome, the altered microbiome triggers immune responses, and those immune responses raise blood pressure.
The practical question this raises is whether reversing those changes through diet could produce real results. A testable version of that idea would pair daily sodium reduction with a Lactobacillus-rich fermented food and measure whether adults with existing hypertension see larger blood pressure drops than those making either change alone, tracked over eight weeks with home monitoring. No published trial has tested that exact combination in a controlled setting. The hypothesis is plausible based on the mechanistic evidence, but it remains unproven in the way that would let a doctor write it on a prescription pad.
Fecal transplants, mice, and the case for causation
Correlation between gut bacteria and blood pressure, even in a study of nearly 7,000 people, does not prove that one causes the other. The strongest evidence for a causal link comes from a different kind of experiment entirely. Researchers collected fecal samples from people diagnosed with hypertension and transplanted them into germ-free mice, animals raised without any gut bacteria of their own. The mice that received microbiota from hypertensive donors developed elevated blood pressure. Mice that received samples from people with normal readings did not.
That result is significant because it isolates the microbiome as a variable. The mice shared no genetics, no lifestyle habits, and no stress levels with the human donors. The only thing transferred was the bacterial community, and it was enough to shift blood pressure upward. The AHA advisory treats this transplant evidence as a key reason to move beyond observational studies and begin thinking about the microbiome as a modifiable risk factor, not just an interesting biomarker.
The Hypertension journal, also published by the AHA, has assembled an editorial collection of heavily cited primary studies on gut microbiome and blood pressure, signaling that the association’s own editorial leadership views this as a field with enough weight to guide clinical thinking. The advisory itself, summarized by Harvard Health Publishing, frames the connection in accessible terms: a healthy gut may help keep blood pressure in check.
Missing trials and open questions for patients
The gap between laboratory evidence and bedside advice remains wide. No large-scale randomized controlled trial has yet tested whether adding specific bacterial strains, whether through fermented foods, probiotic supplements, or targeted microbiome therapies, lowers blood pressure in people already being treated for hypertension. The existing human data is observational or drawn from small challenge studies. Animal transplant experiments demonstrate that gut bacteria can drive blood pressure changes, but mice are not people, and germ-free conditions do not exist outside a laboratory.
There are also unanswered questions about individual variation. The 6,953-person cohort study identified associations at the population level, but gut microbiomes differ enormously from person to person based on geography, genetics, medication use, and diet history. Whether a single dietary intervention, such as adding kimchi or kefir, would shift the right bacterial populations in any given individual is unknown. Sodium sensitivity itself varies widely; some people see sharp blood pressure increases with added salt while others do not, and the microbiome may help explain part of that difference.
The AHA advisory also stops short of recommending specific probiotic products. That restraint is intentional. Commercial probiotics vary in strain, dose, and quality control, and most have not been tested in rigorous hypertension trials. The advisory instead emphasizes established blood pressure strategies-such as reducing sodium, following a plant-forward eating pattern, exercising regularly, limiting alcohol, and not smoking-while acknowledging that these same behaviors tend to foster a more diverse and stable gut microbiome.
For patients, that can feel unsatisfying. The idea of “fixing” blood pressure with a targeted capsule of bacteria is appealingly simple compared with the daily work of changing diet and activity. But the current evidence base does not justify replacing standard treatments with microbiome-focused products. At most, clinicians might view fermented foods and fiber-rich meals as potentially helpful adjuncts layered on top of proven therapies like ACE inhibitors, calcium channel blockers, or thiazide diuretics.
How the advisory may shape future care
Even without prescribing particular strains, the AHA’s move has practical implications. By framing the gut microbiome as part of cardiovascular health, it encourages researchers to design the kinds of trials that are still missing: randomized comparisons of different dietary patterns, probiotic formulations, or even fecal microbiota transplants in carefully selected patient groups with hypertension.
It may also change how clinicians talk with patients about diet. Instead of presenting sodium limits and vegetable intake purely as ways to reduce fluid retention or provide potassium, physicians can explain that these choices influence the ecosystem of microbes that, in turn, shape immune tone and vascular function. For some patients, that systems-level explanation may make lifestyle changes feel more meaningful and less arbitrary.
In the longer term, if specific microbial signatures of salt sensitivity or treatment resistance are validated, stool testing could become one more tool for personalizing hypertension care. A patient whose microbiome suggests a strong inflammatory response to salt might be counseled more aggressively on sodium restriction, while another with a different profile might benefit from tailored prebiotic or probiotic combinations. Those applications remain speculative, but the advisory effectively invites this line of investigation.
What people with high blood pressure can do now
For now, the most evidence-aligned steps are familiar ones, reframed through the microbiome lens. Eating a variety of plant foods-vegetables, fruits, legumes, whole grains, nuts, and seeds-provides fermentable fibers that nourish beneficial bacteria. Limiting highly processed foods and excess salt helps avoid the microbiome disruptions seen in experimental salt-loading studies. Including modest amounts of traditionally fermented foods such as yogurt, kefir, kimchi, or sauerkraut is reasonable for most people, provided they fit within overall calorie and sodium goals.
Crucially, none of these measures should replace prescribed blood pressure medications or regular monitoring. Instead, they can complement standard care while the science catches up. As researchers build on the foundation highlighted in the AHA advisory, patients and clinicians will be watching closely to see whether tomorrow’s hypertension guidelines include not just drug classes and target numbers, but also recommended ways to cultivate a heart-protective gut.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
